Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, has expanded its AbZelectPRO cell line development (CLD) platform with the launch of two next-generation Glutamine Synthetase (GS) knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins. The addition of the new GS knockout cell lines aims to further enhance speed, scalability, and flexibility for biopharma customers. Named AbZelectPRO-KO and AbZelectPRO-KO+, the new...